Search Results
79 results found for "Elizabeth S. Dean"
- The Adhesion GPCR VLGR1/ADGRV1 Regulates the Ca2+ Homeostasis at Mitochondria-Associated ER Membrane
in VLGR1 have been associated with the human Usher syndrome (USH), the most common form of inherited deaf-blindness
- Comparative study of neuropeptide signaling systems in Hemiptera
Although they form an ancient signaling system, there is still a great deal of variety in neuropeptides
- 📰 GPCR Weekly News, February 27 to March 5, 2023
Development of Precision Medicine Platform Sosei Heptares and Neurocrine Biosciences won Top Out-Licensing Deal on the 8th annual Japan Deal of the Year Call for GPCR Papers GPCRs: Signal Transduction.
- 📢 GPCR Update: August 19-25, 2024 | Thrilling Announcement: New Pharmacology Course Dates & Exclusive Discounts Inside!
Dear GPCR Enthusiasts , Get ready for an exciting learning experience with our newly updated Principles
- Embark on a GPCR Adventure: Your Weekly Research Expedition! | Oct 21-27, 2024
from ARPA-H’s Sprint for Women’s Health Nxera Pharma Wins Biotech Company of the Year and Financing Deal
- 📰 GPCR Weekly News, October 23 to 29, 2023
Progress Parker Moss to Join Exscientia as EVP, Corporate Development Confo Therapeutics Nominated for 'Deal
- 📰 GPCR Weekly News, January 16 to 22, 2023
Advanced Therapy Showcase in Tokyo, Japan, organized by LINK-J Jounce takes the cash under amended deal
- All Aboard the GPCR Express: Your Weekly Update is here! Oct 14-20, 2024
Exclusive Deal for Scientists in Developing Nations If you reside and work in a developing country, complete
- 📰 GPCR Weekly Buzz: Exciting Schedule Shifts for Principles of Pharmacology I & II | August 12-18, 2024
Dear GPCR Community, Before diving into this week's news, prepare for an incredible learning journey!
- 📰 GPCR Weekly News, September 25 to October 1, 2023
Septerna sells GPCR program to Vertex for $48 million Merck KGgA collaborates with Exscientia plc in deal
- 📰 GPCR Weekly News, September 18 to 24, 2023
antagonists BenevolentAI, Exscientia on the comeback trail after securing separate AI drug discovery deals
- Discover the Hottest GPCR News of the Week: Oct 7-13, 2024!
Exclusive Deal for Scientists in Developing Nations If you reside and work in a developing country, complete
- 📰 GPCR Weekly News, April 15 to 21, 2024
GPCR phosphorylation immunoassay GPCR Binders, Drugs, and more Identification of 1,3,8-triazaspiro[4.5]decane Drug Discovery Nexus Salipro Biotech will participate in BioKorea2024 Domain Therapeutics Appoints Sean
- GPCR Buzz of the Week | Sep 23 - 29, 2024
Exclusive Deal for Scientists Residing and Working in Developing Nations If you live and work in a developing
- 📢 Early Bird Registration Ends Tomorrow! | Sep 16 - 22, 2024
Exclusive Deal for Scientists Residing and Working in Developing Nations If you live and work in a developing
- 📰 GPCR Weekly News, January 22 to 28, 2024
to progress its proprietary CCR8 antibody candidate to the clinic Novo strikes another obesity drug deal
- GPCR Weekly Whirlwind: Top Receptor Highlights from Sep 30 - Oct 6, 2024!
Exclusive Deal for Scientists in Developing Nations If you reside and work in a developing country, complete
- GPCRs are not simple on-off switches: deep dive into GPCR-ligand interactions
This is particularly important when dealing with receptor subtypes that exhibit significant similarity
- Transformative GPCR Insights: Unleash New Horizons in Science | Sep 9 - 15, 2024
Exclusive Deal for Scientists Residing and Working in Developing Nations If you live and work in a developing
- 📰 GPCR Weekly News
Industry News Sosei Heptares and Neurocrine Biosciences won Out-Licensing Deal of the Year from Locust
- Exciting GPCR Events for Next Year! + GPCR Weekly Rocket Launch ⦿ Oct 28 - Nov 3, 2024
Being a premium member means you get to enjoy all the freebies plus: Access to the recorded classes Discounted GPCR courses - because who doesn't love a good deal?
- Targeting Intracellular Allosteric Sites in GPCRs
This is particularly important when dealing with receptor subtypes that exhibit significant similarity
- Unlocking the Therapeutic Potential of Previously Undruggable GPCRs
to optimize transmembrane domain providing significantly increased binding affinity and providing a means molecules in the library are specific for the target receptor rather than irrelevant cell surface targets, meaning Since shape space exploration is specifically focused on the ‘message’ site in the TM domain, this means This leads to strikingly long in vitro receptor occupancy durations (at least seven days), meaning that There is a great deal of scientific and business interest in solving this problem, and the last two years